B-Raf IN 7

• UNSPSC Description:

  B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM[1].

• Target Antigen:

  Raf

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/b-raf-in-7.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=C(N)N(C2=CC=C(C(CC3)=NNC3=O)C=C2)N=N1)OCC

• Molecular Weight:

  328.33

• References & Citations:

  [1]Thabit MG, et al. Design, synthesis and molecular modeling of phenyl dihydropyridazinone derivatives as B-Raf inhibitors with anticancer activity. Bioorg Chem. 2020 Oct;103:104148.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2477725-07-6